about
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxinsTargeting hypoxia in cancer therapyRadical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides.4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.Acridine Derivatives as Inhibitors of the IRE1α-XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma.Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumorsChemical Space Mimicry for Drug Discovery.Hypoxia-directed drug strategies to target the tumor microenvironment.Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro.SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cellsEfficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers.Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Spin trapping of radicals other than the *OH radical upon reduction of the anticancer agent tirapazamine by cytochrome P450 reductase.Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction.Enhanced conversion of DNA radical damage to double strand breaks by 1,2,4-benzotriazine 1,4-dioxides linked to a DNA binder compared to tirapazamine.Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000.Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.Dynamin impacts homology-directed repair and breast cancer response to chemotherapyTargeting growth hormone function: strategies and therapeutic applicationsStudies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
P50
Q24651122-2E79A22D-86DB-444A-9143-A44D5DC740CCQ29615491-833D7F3A-D75B-4C0A-BD38-0AFCB71D8363Q30990659-40D64532-0FE5-4095-9BE0-79480A80AB17Q31112620-58B0163C-9822-4C48-86A2-256B4E162EB8Q33728365-CD17B8A7-9147-49D7-A58F-83F6105E8CD4Q36053744-C0325C59-0F2A-482A-AAD8-070430B4156BQ36079855-F1AB5BB6-7B82-419A-8CDC-D5AFA8C2F071Q36296461-11C94136-3AB4-4998-B83E-EDB7451AEE86Q38165838-CDEFDE59-BC5B-49F2-94CC-947EE67ABA45Q39013516-F458D84D-F619-4E52-917E-5256FB8E0F22Q39037619-837F9CC9-ED05-46EE-ABF9-B7770810B669Q39428854-822F5075-B722-461F-B9E9-6D9844D01866Q39432031-757C6BC0-838D-4FD1-B5ED-B795BE885B09Q39544675-32047F76-6A59-4CAD-832B-97270FA54E58Q39668588-B437ABBC-1101-4F68-8D4E-F53D8AD8A884Q40041887-F3BB63BF-F444-4434-B262-5F93604203DDQ40052190-1AECEC47-34D0-4327-93DA-DCF43084C9C7Q40418398-C10F8477-E8AA-4882-857B-422F5872D74AQ40595394-7DBCE757-DB57-470B-8863-DF405D6F1693Q40601443-322FEDD8-2559-4C06-A38D-5F4405C2B4EAQ40612485-FEB1433B-7BF8-4A52-8E36-0D16546C07E9Q40644244-B1E51FF6-5E86-46FC-A8EF-D94B75FC4C8CQ40932654-3B047EC1-B059-4F6E-9A4A-0DCA37E75A36Q41343573-41355C7B-C8FA-49B1-9C68-9FBD8528ECFDQ41370914-927261F7-0546-4478-8523-A171ED5345A8Q41488220-F8E57E77-8161-456E-AFD7-B4F107805826Q43169153-859593EE-D3F9-4848-BCA8-A9D1E99256E1Q43273108-25F6D861-9A6E-420C-9F82-FCB62D1840F3Q44262359-B2EE4CCC-DAE7-43E7-A0E9-51DEFD7150FDQ44277187-D5AADAC6-2A92-4825-8998-3872FBA1011FQ44654629-BA482B34-A6F6-4066-B9E1-241992B2A947Q44948284-777A975C-0B53-435C-8689-11DD2C23F46BQ45268973-7D664A98-DBC1-4505-BA66-E4E9ADF8E39DQ46877121-D283B5C4-0F85-4954-A7A7-A21AE5EA6997Q46905097-2CE72785-8E7B-4124-AACF-B3EFAEBEF842Q48099382-930996C8-6DBA-4C04-9AE0-F84096E990CCQ51762831-D42DC199-B255-4931-99F9-B91C8B2C4434Q58104057-9BB41A63-A6D0-492B-B2D1-5627AEB5FE03Q61797690-1C704B19-3CDB-4DBA-84B5-C45D5E75C96FQ64250089-19AFBE72-323F-468E-A498-EC0D20826F85
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael P. Hay
@ast
Michael P. Hay
@en
Michael P. Hay
@es
Michael P. Hay
@sl
type
label
Michael P. Hay
@ast
Michael P. Hay
@en
Michael P. Hay
@es
Michael P. Hay
@sl
prefLabel
Michael P. Hay
@ast
Michael P. Hay
@en
Michael P. Hay
@es
Michael P. Hay
@sl
P106
P1153
7102838425
P2038
Michael_Hay2
P21
P2798
P31
P3835
michael-p-hay
P496
0000-0002-7087-9087